BioSpecifics Technologies (NASDAQ:BSTC) is a commercial-stage biotech company engaged in the development and commercialization of injectable collagenase for a broad range of clinical indications. Currently injectable collagenase is marketed as Xiaflex for a condition known as Dupuytren's Contracture. BioSpecifics has tremendous opportunities in Xiaflex and the shares of the company have huge upside potential over the medium-term.
BioSpecifics is currently conducting Phase II clinical trials of Xiaflex for two indications, human lipoma and canine lipoma. BioSpecifics is not the only company developing Xiaflex. In fact, its strategic partner Auxilium (NASDAQ:AUXL) has been marketing Xiaflex for Dupuytren's Contracture and conducting clinical trials of Xiaflex for Peyronie's Disease, Frozen Shoulder (Adhesive Capsulitis) and Cellulite (Edematous Fibrosclerotic
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|